



FOR IMMEDIATE RELEASE

Nomir Medical Announces Publication of Mechanism-of-Action Data for its Noveon® Dual-Wavelength Device

-Paper in *Photochemistry and Photobiology* Also Details Favorable Efficacy and Safety Data Against Bacterial and Fungal Pathogens-

Waltham, MA – September 15, 2009 - Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the publication of a scientific paper in the journal *Photochemistry and Photobiology* that details *in vitro* and human data demonstrating the unique and patented mechanism-of-action for its Noveon® dual-wavelength device, as well as positive efficacy and safety data. Noveon is a light-based system that photo-biologically targets the elimination of bacterial and fungal infections through a unique, near-infrared, photo-inactivation effect, while preserving healthy tissue and promoting recovery.

“This publication provides important information about the efficacy and side-effect profile of Noveon in multiple classes of infectious disease pathogens, as well as the underlying mechanism-of-action that produces its photo-inactivation effect,” said Eric Bornstein, D.M.D., Chief Scientist of Nomir and lead author on the paper. “It is essential that potential light-based therapies for infectious disease be nontoxic to surrounding healthy human tissue. In the past, UV wavelengths have been used to photo-damage pathogens, but unfortunately, UV light is also photo-carcinogenic to human cells, necessitating the study of other phototherapy-based treatments for infectious disease. We believe the selective aspect of near-infrared photo-inactivation provided by Noveon highlights its potential for the treatment of a broad range of infectious diseases. The Noveon is the first system to produce statistical evidence of safe photo-damage to resistant bacterial pathogens like MRSA and fungal pathogens such as *C. albicans* and *T. rubrum*, all at physiologic temperatures.”

The Noveon system employs dual-wavelengths of 870 and 930 nanometer, wavelengths that have previously been shown to exhibit cellular photo-damaging properties only in optical traps. In the *in vitro* study utilizing Noveon against several bacterial and fungal species, Nomir scientists measured a decrease in trans-membrane potentials (a measure of the robustness of cellular bioenergetics) and an increase in reactive oxygen species (ROS) in the cells. Therefore, Noveon’s mechanism-of-action involves selective damage to the pathogens by the endogenously generated ROS. This phenomenon is referred to as the patent-pending “optically mediated mechano-transduction of cellular redox pathways.”

Results of the *in vitro* studies demonstrate photo-inactivation of 98% of *S. aureus* colonies and of 97% of *E. coli* colonies, versus control, at physiologic temperatures. Additionally, complete photo-inactivation of 100% of *T. rubrum* and *C. albicans* colonies was achieved versus control.

Results of the MRSA human pilot study demonstrate that erythromycin-resistant MRSA and erythromycin-resistant MSSA were completely cleared in all carriers after two Noveon treatments with the addition of 2% topical erythromycin to the treatment area. This is the first known near-infrared potentiation of a first-generation macrolide antibiotic against MRSA in humans with safe near-infrared therapy. No negative sequelae or adverse

events were observed, and the average maximum temperature associated with treatment was well within levels considered safe for human phototherapy and thermal tissue damage thresholds.

In the detailed onychomycosis (toenail fungus) human pilot study, all seven patients reached a mycological negative culture at 60 days following treatment. No negative sequelae or adverse events were observed, and experimental temperatures were again well within accepted safety levels.

“Because of the significant and encouraging data we have seen in our studies, including the present study, Nimir has been pursuing FDA 510(k) clearance for Noveon for the treatment of onychomycosis,” said Richard Burt, President and CEO of Nimir. “We look forward to making this therapy-altering device available to clinicians and patients soon, and are also studying several additional therapeutic indications for the device, including the treatment of diabetic foot ulcers and MRSA infection.”

About Nimir

Nimir Medical Technologies, Inc. is a medical device and photobiology company with a product pipeline of optical energy therapeutics being developed for multiple clinical applications. Nimir’s light-based systems target the elimination of bacterial and fungal infections, while also promoting healthy tissue recovery. This potential therapy-altering technology may enhance the effectiveness of, or even reduce the need for antibiotics and antifungal agents, and may be associated with fewer treatment side-effects. Nimir has a broad patent portfolio with multiple patents and patents pending on systems, methods and unique photobiological mechanism claims for near-infrared photodamage to bacterial and fungal pathogens. www.nomirmedical.com

Forward looking statement

Certain statements contained in this press release containing words like believe, intend, may, expect, project and other similar expressions are forward-looking statements involving a number of risks and uncertainties. Factors that can cause actual results to differ materially from those projected in the Company’s forward-looking statements include the following: market acceptance of our technologies, therapies, and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapidly changing technologies; government regulations of our technologies; our ability to assert and enforce our intellectual property rights and protect our proprietary technologies; the ability to attract and retain key employees; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key milestones in key products and other risks factors from time to time in the Company’s announcements.

Contacts:

Media:

Jennifer Conrad
MacDougall Biomedical Communications
(781) 235-3060

Richard Burt
Chief Executive Officer
Nimir Medical
(781) 893-1000 ext. 403

###